Gilead Recalls 2 Lots Of Remdesivir
The recall involves 2 lots of 100 mg of remdesivir for injection to the user level.
On Friday, Gilead Sciences announced a voluntary recall of 2 lots of Veklury (remdesivir 100 mg for injection) to the user level. The company received a customer complaint, confirmed by the firm’s investigation, of the presence of glass particulates.
The 2 recalled lots are the following:
The company announced the recall and disclosed this risk statement. "The administration of an injectable product that contains glass particulates may result in local irritation or swelling in response to the foreign material. If the glass particulate reaches the blood vessels it can travel to various organs and block blood vessels in the heart, lungs or brain which can cause stroke and even lead to death. To date, Gilead Sciences Inc. has not received any reports of adverse events related to this recall."
Gilead is reaching out to its distributors and customers via UPS next day air mail to hospital pharmacies and is facilitating the return of any remaining vials from the affected lots. Hospitals that have remdesivir which is being recalled should stop using the affected lots and return the product vials per the instructions.
Consumers with questions regarding this recall can contact Gilead Medical Information at 1-866-633-4474 Monday to Friday 6am - 4pm PST or through their website at www.askgileadmedical.com.
Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.